Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Rachael Seiler

Urology Fredericksburg, VA Physician Assistant

NPI 1033744222 CMS profile 7526661

1051 Care Way, Fredericksburg, VA 22401

Open in the dashboard

General payments

$783

38 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Rachael Seiler of Fredericksburg, VA is reported in the CMS Open Payments database as having received $783 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $120 4
2022 General $391 22
2021 General $271 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachael Seiler
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Rachael Seiler were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Rachael Seiler Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $271 $358 $111–$1,000 $132
2022 $391 $476 $143–$1,263 $149
2023 $120 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Astellas Pharma US Inc $193 8 payments
  2. Janssen Biotech, Inc. $114 6 payments
  3. Blue Earth Diagnostics Limited $75 4 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $68 4 payments
  5. ConvaTec Inc. $64 2 payments
  6. Pfizer Inc. $53 3 payments
  7. Antares Pharma, Inc. $44 1 payment
  8. Olympus America Inc. $35 2 payments
  9. Urovant Sciences Inc $32 2 payments
  10. Axonics Modulation Technologies, Inc. $29 2 payments
  11. Other $76 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $718 37 payments
  2. Education $65 1 payment
Products named General payments · program years 2021–2023
  1. MYRBETRIQ $128 7 payments
  2. ERLEADA $114 6 payments
  3. XTANDI $77 4 payments
  4. Nubeqa $68 4 payments
  5. GentleCath $64 2 payments
  6. Xofigo $56 3 payments
  7. ORGOVYX Oncology $53 3 payments
  8. ORGOVYX Hormone Therapy $45 2 payments
  9. NOCDURNA $44 1 payment
  10. Axumin $38 2 payments
  11. Other $221 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

277

Median for Physician Assistant: 241

Drug cost

$1,719

Median for Physician Assistant: $4,110

Branded share of claims

22.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 69 $506
Diclofenac Sodium Generic 12 $268
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $195
Ondansetron Odt Ondansetron Brand 14 $161
Fluticasone Propionate Generic 20 $149
Cephalexin Generic 25 $108
Azithromycin Generic 19 $90
Cyclobenzaprine Hcl Generic 30 $88
Naproxen Generic 17 $73
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $62

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$14,873

Medicare's payments for the services billed

Medicare patients

168

Average age 72

Services billed

186

116 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 39%
Ischemic heart disease 30%
Chronic kidney disease 29%
Heart failure 27%
Depression 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record